CEO of U.S. Bio Company Sells Hundreds of Millions in Stock Shares Continuously... Activates Pre-Planned Option Exercise

United Therapeutics Corp (NASDAQ: UTHR) Chairman and CEO Martin Rosblatt exercised 9,500 stock options on each of March 31, April 2 and April 6, then sold all shares the same days on the open market at roughly $550–590 per share, generating approximately $16 million (about KRW 20 billion) in proceeds. These trades were disclosed as part of a Rule 10b5-1 trading plan established in November 2025 to systematically exercise some 1.73 million options maturing in March 2027. Following the sales, Rosblatt still holds several hundred thousand shares in his own name, through his spouse and via family trusts. On April 1, a large block of options was transferred without cash consideration among trusts effectively controlled by Rosblatt for estate-planning purposes.

On March 9, the company approved a new share repurchase program authorizing up to $2 billion (approximately KRW 2.8 trillion) over the next 12 months, and simultaneously entered into an accelerated repurchase agreement for $1.5 billion (about KRW 2 trillion) to be executed immediately. Additionally, on April 22 United Therapeutics announced it will release first-quarter 2026 financial results before U.S. market open on Wednesday, May 6, followed by a morning webcast to review the earnings.

United Therapeutics is a U.S. biotech company developing therapies for rare and severe pulmonary diseases—such as pulmonary arterial hypertension—and organ manufacturing and transplantation technologies. The company maintains dual headquarters in Silver Spring, Maryland, and Research Triangle Park, North Carolina. Founded in 1996 by Martin Rosblatt after his work on a life-threatening lung disease treatment for his daughter, United Therapeutics has expanded its business around pulmonary disease therapies and its organ-manufacturing and transplantation platform.